touchONCOLOGY caught up with Professor Angela Lamarca (Christie NHS Foundation Trust, Manchester, UK) to discuss her highlights from the Liver Cancer Summit 2022, targeted therapies for cholangiocarcinoma and some of the most important current trial data in hepatic-biliary oncology (the HIMALAYA and TOPAZ-1 studies).
- What were your highlights and hot topics from the Liver Cancer Summit 2022? 00:20-00:58
- How are targeted therapies changing the treatment paradigm for cholangiocarcinoma? 00:58-02:07
- Could you tell us a little about the HIMALAYA study? 02:07-02:48
- How will the results from the phase III TOPAZ-1 trial impact clinical practice for patients with advanced cholangiocarcinoma? 02:48-03:17
- What do you consider the main unmet educational needs in hepatic-biliary oncology? 03:17-04:04
Speaker Disclosure: Angela Lamarca has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the Liver Cancer Summit 2022
